Company
Haleon plc
Headquarters: Weybridge, United Kingdom
Founded: 18 July 2022
CEO: Brian McNamara
Market Cap
£29.90 Billion
GBP as of July 1, 2023
US$37.99 Billion
United Kingdom
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
Zoetis Inc.
|
$78.54 B |
MERCK Kommanditgesellschaft auf Aktien
|
$70.69 B |
Takeda Pharmaceutical Company Limited
|
$46.59 B |
|
Eisai Co. Ltd
|
$17.26 B |
|
PPD, Inc.
|
$16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.